Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NT$ 17.7
Key Takeaways
Risk factor
Meaningful price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for ameliorating fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia and menstrual discomfort. Its pre-clinical stage products include SNA-03 and SNA-07 for cancer immune therapy; SNP-630...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is overpriced on P/FCF.
Data is available to registered users only
Buy
Sell